Bendamustin (B) and rituximab (R) in the treatment of relapsed indolent CD 20+ non-Hodgkin-lymphoma - A phase II study of The East German Study Group of haematology and oncology (OSHO # 072)

被引：0
|
作者：
Lakner, V. [1 ]
Eschenburg, H. [1 ]
Aldaoud, A. [1 ]
Uhlig, J. [1 ]
机构：
[1] Praxis, Leipzig, Germany
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：209 / 210
页数：2
相关论文
共 50 条
  • [31] Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
    Sehn, Laurie H.
    Goy, Andre
    Offner, Fritz C.
    Martinelli, Giovanni
    Caballero, M. Dolores
    Gadeberg, Ole
    Baetz, Tara
    Zelenetz, Andrew D.
    Gaidano, Gianluca
    Fayad, Luis E.
    Buckstein, Rena
    Friedberg, Jonathan W.
    Crump, Michael
    Jaksic, Branimir
    Zinzani, Pier Luigi
    Iyer, Swaminathan Padmanabhan
    Sahin, Deniz
    Chai, Akiko
    Fingerle-Rowson, Guenter
    Press, Oliver W.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (30) : 3467 - +
  • [32] Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
    Ohmachi, Ken
    Ando, Kiyoshi
    Ogura, Michinori
    Uchida, Toshiki
    Itoh, Kuniaki
    Kubota, Nobuko
    Ishizawa, Kenichi
    Yamamoto, Joji
    Watanabe, Takashi
    Uike, Naokuni
    Choi, Ilseung
    Terui, Yasuhito
    Usuki, Kensuke
    Nagai, Hirokazu
    Uoshima, Nobuhiko
    Tobinai, Kensei
    CANCER SCIENCE, 2010, 101 (09) : 2059 - 2064
  • [33] Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group
    Scheubeck, Gabriel
    Hoffmann, Martin
    Jurinovic, Vindi
    Fischer, Luca
    Unterhalt, Michael
    Schmidt, Christian
    Boeck, Hans-Peter
    Duehrsen, Ulrich
    Kaesberger, Joachim
    Kremers, Stephan
    Lindemann, Hans-Walter
    Mantovani, Luisa
    Hiddemann, Wolfgang
    Hoster, Eva
    Dreyling, Martin
    ANNALS OF HEMATOLOGY, 2024, 103 (07) : 2373 - 2380
  • [34] TREATMENT OF MANTLE CELL LYMPHOMA BY ALLOGENEIC STEM CELL TRANSPLANTATION - A PRELIMINARY REPORT FROM THE TRIALS #060 AND #074 OF THE EAST GERMAN STUDY GROUP FOR HAEMATOLOGY AND ONCOLOGY (OSHO)
    Krueger, W. H.
    Basara, N.
    Schueler, F.
    Niederwieser, D.
    Behre, G.
    Grobe, N.
    Sayer, H.
    Maschmeyer, G.
    Haas, A.
    Kiefer, T.
    Neumann, T.
    Doelken, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 291 - 291
  • [35] A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
    Ogura, Michinori
    Ando, Kiyoshi
    Suzuki, Tatsuya
    Ishizawa, Kenichi
    Oh, Sung Yong
    Itoh, Kuniaki
    Yamamoto, Kazuhito
    Au, Wing Yan
    Tien, Hwei-Fang
    Matsuno, Yoshihiro
    Terauchi, Takashi
    Yamamoto, Keiko
    Mori, Masahiko
    Tanaka, Yoshinobu
    Shimamoto, Takashi
    Tobinai, Kensei
    Kim, Won Seog
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (06) : 768 - 776
  • [36] A phase II, multicenter study of bendamustine HCl plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin's lymphoma (NHL).
    Williams, M. E.
    Cohen, P.
    Tulpule, A.
    Van der Jagt, R. H.
    Herst, J. A.
    Bessudo, A.
    Lemieux, B.
    Schwartzberg, L. S.
    Oliver, J. W.
    Robinson, K. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 429S - 429S
  • [37] A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)
    Rossi, Giuseppe
    Prince, Henry Miles
    Tam, Constantine S.
    Ku, Matthew
    Thieblemont, Catherine
    Popplewell, Leslie L.
    Wermke, Martin
    Haioun, Corinne
    Doo, Nicole Wong
    Viardot, Andreas
    Ferreri, Andres J. M.
    Ferrari, Silvia
    Wong, Hansen L.
    Kadu, Priti
    Zugmaier, Gerhard
    Zeng, Yi
    Rambaldi, Alessandro
    BLOOD, 2021, 138
  • [38] AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
    Leonard, John P.
    Trneny, Marek
    Izutsu, Koji
    Fowler, Nathan H.
    Hong, Xiaonan
    Zhu, Jun
    Zhang, Huilai
    Offner, Fritz
    Scheliga, Adriana
    Nowakowski, Grzegorz S.
    Pinto, Antonio
    Re, Francesca
    Fogliatto, Laura Maria
    Scheinberg, Phillip
    Flinn, Ian W.
    Moreira, Claudia
    Liu, David
    Kalambakas, Stacey
    Fustier, Pierre
    Wu, Chengqing
    Gribben, John G.
    BLOOD, 2018, 132
  • [39] THE SAFETY AND EFFICACY OF AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED AND REFRACTORY/RELAPSED AML NOT ELIGIBLE FOR OR RESISTANT TO CHEMOTHERAPY: A MULTI-CENTER PHASE I/II-STUDY OF THE EAST GERMAN HAEMATOLOGY AND ONCOLOGY STUDY GROUP (OSHO)
    Al-Ali, H. K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 343 - 343
  • [40] Rituximab in relapsed lymphocyte-predominant Hodgkin's lymphoma:: Long-term results of a phase-II trial by the German Hodgkin lymphoma Study Group (GHSG)
    Schulz, H.
    Rehwald, U.
    Morschhauser, F.
    Elter, T.
    Driessen, C.
    Ruediger, T.
    Borchmann, P.
    Schnell, R.
    Diehl, V.
    Engert, A.
    Reiser, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 57 - 57
12345